by Max Verhage | Jun 30, 2026 | Blog
Strong science opens doors. A compelling compound, solid preclinical data, and a clear unmet need can secure a grant or attract initial interest. But funding socially responsible drug development from lab to patient requires more than that. Later-stage funders want...
by Max Verhage | Mar 13, 2026 | Blog
Not every promising discovery needs its own company. But making the right venture decision in socially responsible drug development is one of the most consequential choices an academic researcher, clinician, or principal investigator will face. In socially responsible...
by Max Verhage | Feb 5, 2026 | Blog
You probably recognise this situation. You have strong science, promising early data, and a clear potential to help patients. Yet the project risks stalling before it reaches the clinic. Or it moves forward in a way that promises a long and torturous road to get...
by Max Verhage | Dec 9, 2025 | Blog
You’ve spent years developing a promising compound as a professor, clinician, or researcher. The preclinical data looks solid. There’s clear potential to help patients with an unmet medical need. But now you face a tough question: how do you get your...
by Max Verhage | Oct 6, 2025 | Blog
Cystinosis is a rare hereditary disease which leads to accumulation of cystine in the lysosomes causing organ failure. The disease manifests in all organs, but the kidneys and the eyes are affected first. Even though for cystinosis there is a therapy available,...
